HESS-STUMP Holger
No ORCID on file
· 96 papers in corpus
· active 2001-2007
Frequent coauthors
- ZORN Ludwig 64
- HUTH Andreas 64
- KRUEGER MARTIN 64
- MENRAD ANDREAS 64
- THIERAUCH Karl-Heinz 64
- HABEREY MARTIN 64
- INCE STUART 64
- HAENDLER Bernard 32
- CHWALISZ Kristof 32
- LESSEY Bruce 32
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.